Gero: Utilizing whole-exome sequencing data for in-human AI drug discovery
Social Links
What is Gero's Revenue?
Gero's estimated revenue for 2024 is $2.5M.
What does Gero do?
Gero is a longevity biotech company founded by a team of scientists and entrepreneurs with extensive experience in the area of life sciences. Our goal is to extend healthy lifespan dramatically and delay age-related health issues. We identify novel anti-aging targets, develop life-extending therapies and estimate personal risks of diseases and mortality with the help of AI and proprietary models.
Why Gero?
- Gero aims to develop interventions capable of dramatic life extension in humans
- Gero has 5 years of fundamental research in aging
- We discovered that Life extension in humans may be achieved in two ways:
Fighting Frailty (small effect, late in life)
Fighting True Aging (strong effect, early in life), and this is the way we chose unlike other anti-aging companies
- We use causative models for drug discovery, and not correlative like OTHER AI-based longevity companies
- We proved the efficacy of our technology in two species: round worms and in mice.
- We are only one investment round away from getting our proof of concept in humans
Please look at our project whitepaper here: https://www.frontiersin.org/articles/10.3389/fgene.2018.00483/full
More publications here: https://gero.ai/publications
Sorry we could not load this information
You May Also Find These Company Reviews Interesting
Meet glowforge, your at-home 3d laser printer that makes magical things at the push of a button. easily create custom products with a professional laser cutter.... More